DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic ...

A group of lawmakers introduced a proposal Thursday to establish a program for medicinal use of psilocybin mushrooms.

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

The potential legalization of magic mushrooms is heading to Olympia next week as state lawmakers prepare to hear testimony on ...

The Cambridge, Mass., biotechnology company on Thursday said it received a notice of allowance from the U.S. Patent and Trademark Office regarding the drug candidate, ED-003, which is intended to ...

If approved, the 2025 proposals would allow for a two-year development phase before the state starts handing out licenses in ...

The vagus nerve is a key part of the parasympathetic nervous system influencing bodily functions like heart rate digestion ...

Psilocybin significantly reduces confidence in negative self-beliefs four weeks after administration, with effects linked to ...

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...